Home About Login Current Archives Announcements Editorial Board
Submit Now For Authors Call for Submissions Statistics Contact
Home > Archives > Volume 20, No 8 (2022) > Article

DOI: 10.14704/nq.2022.20.8.NQ44186

Crosstalk between Viable Targets: RUNX2 and FXR for Effective Treatment of Prostate Cancer through Regulation of the PTEN

Noor Ghalib Al-hussainy1, InamSameh. Arif2, Basma Talib Al-Sudani3*


Purpose:The aim of the project is to indicate that FXR activation can induce PTEN and BMP-2 expression through RUNX2 down expression, and FXR could be a potential therapeutic target for the treatment of prostate cancer. Methods:Human adenocarcinoma prostate cancer cell lines (PC3) were generally cultured in RPMI1460 media, 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin at 37°C and 5% CO2 using 75 cm3 cell culture flasks and treated with Obeticholic acid INT747 (as FXR agonist). Determination of the viability of PC3 cell line after treatment with different concentrations of INT747 compound by MTT assay. The expressions level of FXR, RUNX2, PTEN, and BMP2 were measured by western blot.


PC3 cell line, INT747, FXR, RUNX2, PTEN and BMP2.

Full Text